Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo
Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5...
Gespeichert in:
Veröffentlicht in: | Pharmacognosy Magazine 2018-04, Vol.14 (55), p.197-207 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 207 |
---|---|
container_issue | 55 |
container_start_page | 197 |
container_title | Pharmacognosy Magazine |
container_volume | 14 |
creator | Ramalingayya, Grandhi Nayak, Pawan Shenoy, Rekha Mallik, Sanchari Gourishetti, Karthik Hussain, Shalam Rao, Chamallamudi Nandakumar, Krishnadas |
description | Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid. |
doi_str_mv | 10.4103/pm.pm_364_17 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2112130626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A545381420</galeid><sourcerecordid>A545381420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</originalsourceid><addsrcrecordid>eNptkU1LAzEQhoMoWKs3f0DAq1vzuR_HUvwoFL3oOWSTbEnpJmuSLe2_N1pRBJnDDC_PzDDzAnCN0YxhRO-Gfjb0gpZM4OoETFBTlQVDJTn9qmmBSVOeg4sYNwjxGqNqAuSzDNatrYOyN1vrg0wmQu33PoytVdYV1ulRGQ2dGYNPfp_FdIBLB3c2BQ-l01D5tbPJ7gzUh9iNTiXr3RHZ-Utw1sltNFffeQreHu5fF0_F6uVxuZivCkUpSgWjJTFVyxtimkq3SFHeYc7rjjXYGMU1M5RipWlTSVyXLJ_SEqw4qyjTlNR0Cm6Oc4fg30cTk9j4Mbi8UhCMCab5EeUvtZZbI6zrfApS9TYqMeeM0xozgjI1-4fKoU1vlXems1n_03B7bFDBxxhMJ4ZgexkOAiPx6Y3Ixvx4Qz8AZGeCKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112130626</pqid></control><display><type>article</type><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</creator><creatorcontrib>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</creatorcontrib><description>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</description><identifier>ISSN: 0973-1296</identifier><identifier>EISSN: 0976-4062</identifier><identifier>DOI: 10.4103/pm.pm_364_17</identifier><language>eng</language><publisher>London: Medknow Publications and Media Pvt. Ltd</publisher><subject>Animal cognition ; Breast cancer ; Cancer therapies ; Care and treatment ; Cell cycle ; Chemo brain ; Chemotherapy ; Cognitive ability ; Complications and side effects ; Cytokines ; Doxorubicin ; Drug dosages ; Drug-induced dyskinesia ; Flavonoids ; Gene expression ; Health aspects ; Memory ; Metabolism ; Metabolites ; Neurotoxicity ; Pharmacognosy ; Pharmacological research ; Physiological aspects ; Reactive oxygen species ; Risk factors ; Rodents ; Studies</subject><ispartof>Pharmacognosy Magazine, 2018-04, Vol.14 (55), p.197-207</ispartof><rights>COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd.</rights><rights>2018. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</citedby><cites>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ramalingayya, Grandhi</creatorcontrib><creatorcontrib>Nayak, Pawan</creatorcontrib><creatorcontrib>Shenoy, Rekha</creatorcontrib><creatorcontrib>Mallik, Sanchari</creatorcontrib><creatorcontrib>Gourishetti, Karthik</creatorcontrib><creatorcontrib>Hussain, Shalam</creatorcontrib><creatorcontrib>Rao, Chamallamudi</creatorcontrib><creatorcontrib>Nandakumar, Krishnadas</creatorcontrib><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><title>Pharmacognosy Magazine</title><description>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</description><subject>Animal cognition</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Chemo brain</subject><subject>Chemotherapy</subject><subject>Cognitive ability</subject><subject>Complications and side effects</subject><subject>Cytokines</subject><subject>Doxorubicin</subject><subject>Drug dosages</subject><subject>Drug-induced dyskinesia</subject><subject>Flavonoids</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Memory</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Neurotoxicity</subject><subject>Pharmacognosy</subject><subject>Pharmacological research</subject><subject>Physiological aspects</subject><subject>Reactive oxygen species</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>Studies</subject><issn>0973-1296</issn><issn>0976-4062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU1LAzEQhoMoWKs3f0DAq1vzuR_HUvwoFL3oOWSTbEnpJmuSLe2_N1pRBJnDDC_PzDDzAnCN0YxhRO-Gfjb0gpZM4OoETFBTlQVDJTn9qmmBSVOeg4sYNwjxGqNqAuSzDNatrYOyN1vrg0wmQu33PoytVdYV1ulRGQ2dGYNPfp_FdIBLB3c2BQ-l01D5tbPJ7gzUh9iNTiXr3RHZ-Utw1sltNFffeQreHu5fF0_F6uVxuZivCkUpSgWjJTFVyxtimkq3SFHeYc7rjjXYGMU1M5RipWlTSVyXLJ_SEqw4qyjTlNR0Cm6Oc4fg30cTk9j4Mbi8UhCMCab5EeUvtZZbI6zrfApS9TYqMeeM0xozgjI1-4fKoU1vlXems1n_03B7bFDBxxhMJ4ZgexkOAiPx6Y3Ixvx4Qz8AZGeCKg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Ramalingayya, Grandhi</creator><creator>Nayak, Pawan</creator><creator>Shenoy, Rekha</creator><creator>Mallik, Sanchari</creator><creator>Gourishetti, Karthik</creator><creator>Hussain, Shalam</creator><creator>Rao, Chamallamudi</creator><creator>Nandakumar, Krishnadas</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20180401</creationdate><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><author>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animal cognition</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Chemo brain</topic><topic>Chemotherapy</topic><topic>Cognitive ability</topic><topic>Complications and side effects</topic><topic>Cytokines</topic><topic>Doxorubicin</topic><topic>Drug dosages</topic><topic>Drug-induced dyskinesia</topic><topic>Flavonoids</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Memory</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Neurotoxicity</topic><topic>Pharmacognosy</topic><topic>Pharmacological research</topic><topic>Physiological aspects</topic><topic>Reactive oxygen species</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramalingayya, Grandhi</creatorcontrib><creatorcontrib>Nayak, Pawan</creatorcontrib><creatorcontrib>Shenoy, Rekha</creatorcontrib><creatorcontrib>Mallik, Sanchari</creatorcontrib><creatorcontrib>Gourishetti, Karthik</creatorcontrib><creatorcontrib>Hussain, Shalam</creatorcontrib><creatorcontrib>Rao, Chamallamudi</creatorcontrib><creatorcontrib>Nandakumar, Krishnadas</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Pharmacognosy Magazine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramalingayya, Grandhi</au><au>Nayak, Pawan</au><au>Shenoy, Rekha</au><au>Mallik, Sanchari</au><au>Gourishetti, Karthik</au><au>Hussain, Shalam</au><au>Rao, Chamallamudi</au><au>Nandakumar, Krishnadas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</atitle><jtitle>Pharmacognosy Magazine</jtitle><date>2018-04-01</date><risdate>2018</risdate><volume>14</volume><issue>55</issue><spage>197</spage><epage>207</epage><pages>197-207</pages><issn>0973-1296</issn><eissn>0976-4062</eissn><abstract>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</abstract><cop>London</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><doi>10.4103/pm.pm_364_17</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0973-1296 |
ispartof | Pharmacognosy Magazine, 2018-04, Vol.14 (55), p.197-207 |
issn | 0973-1296 0976-4062 |
language | eng |
recordid | cdi_proquest_journals_2112130626 |
source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Animal cognition Breast cancer Cancer therapies Care and treatment Cell cycle Chemo brain Chemotherapy Cognitive ability Complications and side effects Cytokines Doxorubicin Drug dosages Drug-induced dyskinesia Flavonoids Gene expression Health aspects Memory Metabolism Metabolites Neurotoxicity Pharmacognosy Pharmacological research Physiological aspects Reactive oxygen species Risk factors Rodents Studies |
title | Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Naringin%20ameliorates%20doxorubicin-induced%20neurotoxicity%20In%20vitro%20and%20cognitive%20dysfunction%20In%20vivo&rft.jtitle=Pharmacognosy%20Magazine&rft.au=Ramalingayya,%20Grandhi&rft.date=2018-04-01&rft.volume=14&rft.issue=55&rft.spage=197&rft.epage=207&rft.pages=197-207&rft.issn=0973-1296&rft.eissn=0976-4062&rft_id=info:doi/10.4103/pm.pm_364_17&rft_dat=%3Cgale_proqu%3EA545381420%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2112130626&rft_id=info:pmid/&rft_galeid=A545381420&rfr_iscdi=true |